AngioDynamics (ANGO) Stock Overview
A medical technology company, designs, manufactures, and sells medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ANGO Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
AngioDynamics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.01 |
| 52 Week High | US$13.99 |
| 52 Week Low | US$8.36 |
| Beta | 0.36 |
| 1 Month Change | 13.33% |
| 3 Month Change | 8.96% |
| 1 Year Change | 36.66% |
| 3 Year Change | 26.07% |
| 5 Year Change | -52.03% |
| Change since IPO | 4.08% |
Recent News & Updates
Recent updates
The Market Doesn't Like What It Sees From AngioDynamics, Inc.'s (NASDAQ:ANGO) Revenues Yet
You may think that with a price-to-sales (or "P/S") ratio of 1.9x AngioDynamics, Inc. ( NASDAQ:ANGO ) is a stock worth...We Think AngioDynamics (NASDAQ:ANGO) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...AngioDynamics: Discounted Sales Multiple With Real Growth Engines
Summary AngioDynamics, Inc. remains a Buy, trading at a steep discount to peers despite double-digit MedTech growth and improving margins. ANGO's Med Tech division now drives 47% of sales, with strong performance from Auryon, AlphaVac, AngioVac, and NanoKnife products. Gross margin improved to 55.3%, operating costs are under control, and management expects positive cash flow and raised guidance for FY 2026. Valuation is attractive, with ANGO's EV/Sales and P/S ratios well below sector averages, supporting significant upside if execution continues. Read the full article on Seeking AlphaRevenues Working Against AngioDynamics, Inc.'s (NASDAQ:ANGO) Share Price
You may think that with a price-to-sales (or "P/S") ratio of 1.3x AngioDynamics, Inc. ( NASDAQ:ANGO ) is a stock worth...
FDA Approval And International Expansion Will Redefine Healthcare Delivery
Growth in proprietary therapies and expanding adoption of key platforms are driving improved margins, higher recurring revenues, and long-term earnings visibility.AngioDynamics, Inc.'s (NASDAQ:ANGO) Share Price Boosted 38% But Its Business Prospects Need A Lift Too
Despite an already strong run, AngioDynamics, Inc. ( NASDAQ:ANGO ) shares have been powering on, with a gain of 38% in...AngioDynamics: Improving Financial Performance And Good Clinical Data Reinvigorate The Shares
Summary AngioDynamics' fiscal Q2'25 results exceeded expectations, with Med Tech growing 25% and delivering better gross margins, boosting confidence in achieving high single-digit revenue growth and double-digit EBITDA margins in time. Clinical data for AlphaVac and NanoKnife were positive relative to established standards of care, suggesting potentially competitive offerings in the pulmonary embolism and prostate cancer markets if management can execute. Auryon, AlphaVac, and NanoKnife all offer double-digit growth potential, but sales execution against larger entrenched rivals is not going to be easy and the Med Device business offers limited potential. Shares have surged over 60%, yet further upside toward $20 remains if management can capitalize on Med Tech opportunities. Read the full article on Seeking AlphaAngioDynamics: A Surgical Approach To Market Growth
Summary AngioDynamics, Inc.'s Q2 2025 earnings beat expectations, with non-GAAP EPS at -$0.04 and revenue at $73.02 million, driving a 35% stock surge. Med Tech division shines, with 25% revenue growth and key products like Auryon, AlphaVac, and AngioVac showing strong performance and market acceptance. NanoKnife's FDA clearance and promising clinical trials highlight its potential in prostate cancer treatment, contributing to a 23.1% rise in disposable revenue. Despite some challenges, AngioDynamics' strategic focus on high-growth markets and a healthy balance sheet make ANGO stock a solid “Buy” for long-term growth. Read the full article on Seeking AlphaThere Is A Reason AngioDynamics, Inc.'s (NASDAQ:ANGO) Price Is Undemanding
You may think that with a price-to-sales (or "P/S") ratio of 1.2x AngioDynamics, Inc. ( NASDAQ:ANGO ) is definitely a...AngioDynamics, Inc. (NASDAQ:ANGO) Just Released Its Annual Results And Analysts Are Updating Their Estimates
Shareholders of AngioDynamics, Inc. ( NASDAQ:ANGO ) will be pleased this week, given that the stock price is up 13% to...Improved Revenues Required Before AngioDynamics, Inc. (NASDAQ:ANGO) Stock's 26% Jump Looks Justified
The AngioDynamics, Inc. ( NASDAQ:ANGO ) share price has done very well over the last month, posting an excellent gain...AngioDynamics: A Story To Monitor
Summary AngioDynamics, Inc. is struggling for profitability and its stock hit an all-time low of $5.26 on March 25th, 2024. However, the company is undergoing a restructuring, eliminating its manufacturing capabilities and focusing on its profitable medical technology business. Despite the challenges, the company has no debt, an increasingly higher margin portfolio, and insider buying, making its valuation potentially compelling. An analysis around AngioDynamics follows in the paragraphs below. Read the full article on Seeking AlphaA Leaner AngioDynamics Is A High-Risk Execution-Driven Story
Summary AngioDynamics has sold low-growth businesses, shifted to an outsourced manufacturing model, and refocused on cardiovascular and oncological care for potential growth. The recent approval of the AlphaVac F18 mechanical thrombectomy system for pulmonary embolism presents a significant opportunity in a large ($2B+) and growing market. The company's historical execution challenges raise concerns, but there is potential for a stronger, more profitable AngioDynamics if products like Auryon, AlphaVac, and NanoKnife are successful. Progress toward double-digit adjusted EBITDA margins in four or five years can support a fair value of $10 today, but this is a highly speculative call. Read the full article on Seeking AlphaAngioDynamics, Inc.'s (NASDAQ:ANGO) Shares Bounce 26% But Its Business Still Trails The Industry
AngioDynamics, Inc. ( NASDAQ:ANGO ) shares have had a really impressive month, gaining 26% after a shaky period...AngioDynamics: Restructuring Initiative May Not Go Far Enough
Summary AngioDynamics' latest quarter earnings missed expectations. The company is facing weaker-than-anticipated sales following the rollout of new products forcing management to revise lower full-year guidance. We expect shares to remain volatile until there is evidence of stronger growth and a path to profitability. Read the full article on Seeking AlphaAngioDynamics (NASDAQ:ANGO) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Despite announcing strong earnings, AngioDynamics, Inc.'s ( NASDAQ:ANGO ) stock was sluggish. Our analysis uncovered...Shareholder Returns
| ANGO | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 5.2% | 4.6% | 0.3% |
| 1Y | 36.7% | -21.2% | 19.9% |
Return vs Industry: ANGO exceeded the US Medical Equipment industry which returned -21.2% over the past year.
Return vs Market: ANGO exceeded the US Market which returned 19.9% over the past year.
Price Volatility
| ANGO volatility | |
|---|---|
| ANGO Average Weekly Movement | 7.1% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ANGO has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ANGO's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 675 | Jim Clemmer | www.angiodynamics.com |
AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium. The company’s thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit for use in extracorporeal circulatory support procedures for periods of up to six hours, as well as with other manufacturers’ off-the-shelf pump, filter, and reinfusion cannula facilitate venous drainage.
AngioDynamics, Inc. Fundamentals Summary
| ANGO fundamental statistics | |
|---|---|
| Market cap | US$550.20m |
| Earnings (TTM) | -US$31.39m |
| Revenue (TTM) | US$313.73m |
Is ANGO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ANGO income statement (TTM) | |
|---|---|
| Revenue | US$313.73m |
| Cost of Revenue | US$143.39m |
| Gross Profit | US$170.34m |
| Other Expenses | US$201.72m |
| Earnings | -US$31.39m |
Last Reported Earnings
Feb 28, 2026
Next Earnings Date
Jul 14, 2026
| Earnings per share (EPS) | -0.75 |
| Gross Margin | 54.30% |
| Net Profit Margin | -10.00% |
| Debt/Equity Ratio | 3.4% |
How did ANGO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/30 21:30 |
| End of Day Share Price | 2026/06/30 00:00 |
| Earnings | 2026/02/28 |
| Annual Earnings | 2025/05/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
AngioDynamics, Inc. is covered by 16 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Matthew Taylor | Barclays |
| John Young | Canaccord Genuity |
| William Plovanic | Canaccord Genuity |